Anticoagulation Management Note (VTE)

Date/Time: [Encounter date and time]

Author/Role: [Name, credentials, and role]

Care Setting: [inpatient / outpatient / ED follow-up]

Indication: [Primary VTE diagnosis and location]

Referral Question: [Specific anticoagulation question] (Include only if applicable)

Clinical Snapshot

[1–3 sentence summary: patient descriptor, VTE type and approximate diagnosis date, provoking classification, current anticoagulant and day of therapy if applicable, and the key decision for this encounter] (If critical details are unknown, explicitly state and note plan to obtain, e.g., "VTE diagnosis date unknown; outside records requested.")

VTE History

[Brief narrative of presenting symptoms, care setting at diagnosis, and current symptom trajectory]

• Date of VTE diagnosis: [Exact or approximate date] (If from outside records or unknown, state source or note plan to obtain)
• Anatomic characterization:
  • DVT: [Side; proximal vs distal; upper vs lower extremity; catheter-associated yes/no] (Include if applicable)
  • PE: [Segmental burden if known; right heart strain indicators; hemodynamic stability at presentation] (Include if applicable)
• Diagnostic certainty: [Objective test modality, date, and result summary] (If pending or from outside records, note status and plan to verify)
• Initial treatment: [Agent initiated; dosing approach; any thrombolysis/thrombectomy/IVC filter with rationale] (Include only interventions performed)
• Current treatment phase: [initial management / primary treatment / secondary prevention] (If transitioning phases, state the decision point and timing)

Provoking Factors

• Major transient risk factors: [Surgery; major trauma; hospitalization with immobility—include dates] (Include only if present)
• Minor transient risk factors: [Estrogen exposure; pregnancy/postpartum; prolonged travel; acute illness—include dates] (Include only if present)
• Persistent/chronic risk factors: [Active cancer with type/status; chronic inflammatory disease; antiphospholipid syndrome; persistent paralysis] (Include only if present)
• Prior VTE history: [Date; provoking factors; duration treated; outcomes] (Include only if present)

Classification: [Provoked by major transient risk factor / provoked by minor transient risk factor / provoked by persistent risk factor / unprovoked / indeterminate] (If indeterminate, briefly explain uncertainty and plan to clarify)

Bleeding Risk Assessment

• Prior major bleeding: [Site, date, circumstances] (Omit if none)
• GI pathology or recent bleed: [Details] (Omit if none)
• Intracranial pathology or prior ICH: [Details] (Omit if none)
• Thrombocytopenia/coagulopathy: [Platelet count and cause; coagulopathy details] (Omit if none)
• Severe uncontrolled hypertension: [Values and context] (Omit if none)
• Renal function: [Creatinine and eGFR with date]
• Hepatic function: [Key labs or clinical hepatic impairment] (Include only if relevant)
• Concomitant bleeding-risk medications: [Antiplatelets; NSAIDs; others] (Omit if none)
• Falls/trauma risk: [Functional context and frequency] (Omit if not elevated)

Bleeding risk summary: [low / moderate / high]; key drivers: [Top 1–3 factors]

Agent Selection Considerations

• Renal function: [eGFR and implications for dosing/eligibility] (Do not infer eligibility without current labs)
• Hepatic function: [Impairment and agent constraints] (Include only if relevant)
• Pregnancy/breastfeeding status: [Status and implications] (Include only if applicable)
• Active cancer: [Type/status; GI malignancy considerations for DOACs] (Include only if applicable)
• Suspected/confirmed antiphospholipid syndrome: [Status; preference for warfarin over DOACs] (Include only if applicable)
• Body weight extremes: [Actual weight/BMI and relevance] (Include only if applicable)
• Swallowing/absorption issues: [Dysphagia; bariatric surgery; malabsorption] (Include only if applicable)
• Adherence feasibility: [Dosing frequency preferences; cognitive/social factors] (Include only if concerns exist)
• Cost/coverage constraints: [Insurance or access barriers] (Include only if materially affecting choice)
• Drug interactions: [Strong CYP3A4/P-gp inhibitors/inducers; antiplatelets; NSAIDs] (Include only if present)

Chosen agent rationale: [Brief statement of why selected agent best balances efficacy, safety, and feasibility for this patient]

Objective Data

• Vitals: [BP; HR; O2 sat with date/time]
• Weight/BMI: [Value(s) with date]
• Pertinent exam: [DVT limb findings; cardiopulmonary findings if symptomatic] (Include only relevant findings)
• Imaging summary: [Test; date; key result]
• Laboratory data: [CBC with Hgb/platelets; creatinine/eGFR; hepatic panel if relevant; PT/INR and aPTT if relevant—include dates]

Assessment

Diagnosis statement: [Acute / chronic] [provoked / unprovoked / indeterminate] [DVT / PE] at [site], diagnosed [date], currently [improving / stable / worsening]. (Do not infer classification when exposure timing is unclear; use indeterminate with brief explanation)

Recurrence risk reasoning: [Concise rationale tied to provoking factor classification and patient-specific factors]

Bleeding risk reasoning: [Concise rationale identifying top drivers influencing agent/dose/duration decisions]

Decision focus for this encounter: [Starting anticoagulation / switching agent / adjusting dose / determining duration / monitoring plan / periprocedural management / adherence support]

Plan

VTE / Anticoagulation Management

1. Anticoagulant regimen: [Drug, dose, route, frequency]. Start [date/time]. (If switching, specify last dose of prior agent and first dose of new agent. If bridging, specify bridging agent, timing, and stop criteria.)
2. Duration: [Intended minimum duration with calendar end date when feasible]. [Extended therapy plan and criteria if applicable]. Reassessment: [interval, e.g., at 3-month visit or annually].
3. Monitoring: Responsible party: [anticoagulation clinic / PCP / hematology]. Clinical monitoring: [bleeding/bruising symptoms; recurrent VTE symptoms; adherence]. Laboratory monitoring: [CBC and renal function interval; INR schedule if warfarin].
4. Concomitant medications: [Antiplatelet/NSAID decisions with rationale]. [Gastric protection if indicated, with rationale.]
5. Bleeding contingency: [Symptoms requiring urgent evaluation; where to seek emergency care; instruction to inform all clinicians/dentists of anticoagulation status].
6. Patient counseling:
   • Purpose of anticoagulation discussed [yes / no]
   • Adherence importance and missed-dose instructions reviewed [yes / no]
   • Bleeding precautions and warning signs reviewed [yes / no]
   • Interaction precautions (OTC NSAIDs, supplements, alcohol) reviewed [yes / no]
   • Pregnancy avoidance/contraception discussed [yes / no / not applicable]
   • Written materials provided [yes / no]
   • Teach-back performed [yes / no]
7. Follow-up: [Timeframe] via [in-person / telehealth]. Focus: [planned topics for next visit].

Periprocedural Anticoagulation Management

[Anticipated procedure and bleeding risk category; whether anticoagulant interruption is expected; who will coordinate the perioperative plan; patient instructed to contact anticoagulation manager before scheduling procedures or holding doses] (Include this section only if relevant)

Additional Problems Affecting Anticoagulation

[Problem name]: [How it changes anticoagulation decisions; pending data; specific plan] (Include only if relevant; examples: CKD, active malignancy, thrombocytopenia/anemia, suspected APS)

Thrombophilia Testing

[Clinical scenario prompting consideration]. [Whether and how results would change management]. [Timing considerations if acute thrombosis or ongoing anticoagulation may affect results]. [Plan for when/how to test.] (Include only if testing is being considered and would change management)

Coordination

[Consultants involved and key discussion points]. [Handoff responsibility: who manages refills, lab review, duration decisions]. [Transition plan if care is transferring.]